Tag Archives: SARS-CoV-2

A URSAPHARM Arzneimittel e a CEBINA anunciam uma parceria com vista a reaproveitar o anti-histamínico azelastina para combater a COVID-19

URSAPHARM Arzneimittel and CEBINA announce partnership to repurpose the antihistamine azelastine to combat COVID-19

(PRESS RELEASE) SAARBRÜCKEN / VIENA, 17-Feb-2021 — /EuropaWire/ — Na luta contra o vírus SARS-CoV-2, um grande número de empresas farmacêuticas está em busca de novas abordagens para combater a pandemia. Além das vacinas, estão a ser feitos esforços intensivos … Read the full press release

URSAPHARM Arzneimittel y CEBINA anuncian una colaboración para readaptar el antihistamínico azelastine para combatir la COVID-19

URSAPHARM Arzneimittel and CEBINA announce partnership to repurpose the antihistamine azelastine to combat COVID-19

(PRESS RELEASE) SAARBRÜCKEN / VIENA, 17-Feb-2021 — /EuropaWire/ — En la lucha contra el virus SARS-CoV-2, una gran cantidad de empresas farmacéuticas están buscando nuevos enfoques para combatir la pandemia. Además de las vacunas, las iniciativas exhaustivas de investigación y … Read the full press release

URSAPHARM Arzneimittel and CEBINA announce partnership to repurpose the antihistamine azelastine to combat COVID-19

URSAPHARM Arzneimittel and CEBINA announce partnership to repurpose the antihistamine azelastine to combat COVID-19

(PRESS RELEASE) SAARBRÜCKEN / VIENNA, 17-Feb-2021 — /EuropaWire/ — In the fight against the SARS-CoV-2 virus, a large number of pharmaceutical companies are looking for new approaches to combat the pandemic. In addition to vaccines, intensive research and development efforts … Read the full press release

University of Liverpool awarded grants to create anti-viral surface technologies to break chain of COVID transmission

(PRESS RELEASE) LIVERPOOL, 25-Jan-2021 — /EuropaWire/ — University of Liverpool announces that its has joined a consortium to develop new anti-viral technology that will limit the transmission of SARS-CoV-2 (Covid-19) from touching contaminated surfaces in areas such as hospitals, train … Read the full press release

EIB signs €15.0 million financing deal with AB Science to support the development of masitinib as a treatment for COVID-19

Financing deal worth €15.0 million signed to support clinical development programme for masitinib Masitinib developed as a credible candidate for treating COVID-19 in addition to other diseases for which no therapeutic solutions are available (PRESS RELEASE) PARIS, 30-Nov-2020 — /EuropaWire/ — … Read the full press release

Roche unveils new Anti-SARS-CoV-2 serology test to quantitatively measure antibodies in people exposed to SARS-CoV-2

The new Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in patients who have been exposed to the virus. The test  targets antibodies against the spike protein. This is the focus of vaccines in development … Read the full press release

Atos opens HPC, AI & Quantum Life Sciences Centre of Excellence at Wellcome Genome Campus in Cambridgeshire, UK

(PRESS RELEASE) LONDON/ PARIS, 8-Jul-2020 — /EuropaWire/ — Digital transformation leader Atos has announced it will launch global HPC, AI & Quantum Life Sciences Centre of Excellence in agreement with Wellcome Genome Campus in Cambridgeshire, UK. The Centre will provide … Read the full press release

Fujirebio Europe: Atila Biosystems’ iAMP COVID-19 Detection Kit has just been CE marked

(PRESS RELEASE) GHENT, 12-May-2020 — /EuropaWire/ — Fujirebio Europe, part of Japanese in vitro diagnostics (IVD) testing leader Fujirebio, has just announced the product it distributes across Europe the iAMP® COVID-19 Detection kit from its partner Atila Biosystems, Inc. of … Read the full press release